Affymetrix Buying Flow Cytometry, Reagent Firm eBioscience for $330M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix today announced a definitive agreement to buy eBioscience, a flow cytometry and immunoassay reagent firm, for $330 million in cash.

The deal is expected to provide the Santa Clara, Calif.-based microarray firm with commercial opportunities in post-genomic applications of immunology, oncology, cell biology, stem cell biology, and diagnostics. Affy also said that it will augment its growing molecular diagnostics business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.